Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

Diabetologia

Volumn 55, Issue 4, 2012, Pages 1186-1194

  Varewijck, A J ^a   Janssen, J A M J L ^a   Vahatalo M ^b   Hofland, L J ^a   Lamberts, S W J ^a   Yki Jarvinen H ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b City of Turku Health Centre   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

IGF I bioactivity; Insulin glargine; Insulin therapy; NPH insulin; Total IGF I; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES CONTROL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; INSULIN-LIKE GROWTH FACTOR I; MALE; METFORMIN; MIDDLE AGED;

EID: 84862553178     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2435-7     Document Type: Article

References (42)

1. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
2. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
3. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765
4. Erratum 52:2469
5. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
6. Food and Drug Administration (2011) FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. Available from www.fda.gov/Drugs/DrugSafety/ucm239376.htm, accessed 12 January 2011.
7. Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005
8. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ, Janssen JA (2010) Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. Growth Horm IGF Res 20:427-431
9. Sciacca L, Cassarino MF, Genua M et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743-1753
10. Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50:2534-2543
11. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41-49
12. Chen JW, Ledet T, Orskov H et al (2003) A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 284:E1149-E1155
13. Brugts MP, Ranke MB, Hofland LJ et al (2008) Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab 93:2539-2545
14. Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33:1997-2003
15. Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116:73-78
16. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442-451
17. Vehkavaara S, Yki-Jarvinen H (2004) 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 24:325-330
18. Owens DR, Bolli GB (2008) Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 10: 333-349
19. Westerbacka J, Bergholm R, Tiikkainen M, Yki-Jarvinen H (2004) Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects. Arterioscler Thromb Vasc Biol 24:320-324
20. Kuerzel GU, Shukla U, Scholtz HE et al (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19:34-40
21. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623
22. Arafat AM, Weickert MO, Frystyk J et al (2009) The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 94:5093-5101
23. Bereket A, Lang CH, Blethen SL, Fan J, Frost RA, Wilson TA (1995) Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 80:2282-2288
24. Bang P, Brismar K, Rosenfeld RG (1994) Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130-to 150-kDa ternary complex. J Clin Endocrinol Metab 78:1119-1127
25. Brugts MP, van Duijn CM, Hofland LJ, Witteman JC, Lamberts SW, Janssen JA (2010) IGF-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 59:505-508
26. Ji S, Guan R, Frank SJ, Messina JL (1999) Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway. J Biol Chem 274:13434-13442
27. Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V (1998) Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 58:353-360
28. Chestnut RE, Quarmby V (2002) Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. J Immunol Methods 259:11-24
29. Janssen JAMJL (2011) IGF-I: pro's and con's of a bioassay. Horm Res Paediatr 76(suppl 1):S106-S110
30. Nagel JM, Staffa J, Renner-Müller I et al (2010) Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 1:320-330
31. Vigneri R, Squatrito S, Sciacca L (2010) Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol 47:271-278
32. Nathan DM, Buse JB, Davidson MB et al (2009) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30
33. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ (Clinical Research Edition) 330:1304-1305
34. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258
35. Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708
36. Jalving M, Gietema JA, Lefrandt JD et al (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46:2369-2380
37. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501-505
38. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928
39. Shaw RJ, Bardeesy N, Manning BD et al (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99
40. Ning J, Clemmons DR (2010) AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 24:1218-1229
41. Kim J, Yoon MY, Choi SL et al (2001) Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1-and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J Biol Chem 276:19102-19110
42. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684-39695